title: Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis.
abstract: A persistent proteinuria is commonly observed in nephrotic patient with focal segmental glomerulosclerosis (FSGS) under treatment with prednisolone+/-cyclophosphamide or with vasodilators (ACEI+AII receptor antagonist, calcium channel blocker and antiplatelet agent). Fourteen such patients with persistent proteinuria were subject to be treated with Ganoderma lucidum. Initial study revealed an enhanced endothelial cell cytotoxicity induced by patient's serum, and an altered immunocirculatory balance with predominant proinflammatory cytokine TNF alpha activity in the presence of defective anti-inflammatory cytokine interleukin-10. Treatment with Ganoderma lucidum suppressed endothelial cell cytotoxicity, restored immunocirculatory balance and successfully suppressed proteinuria in all of these 14 patients.
authors.affiliation: Department of Physiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. fmednft@md2.md.chula.ac.th
authors.forename: Narisa
authors.initials: N
authors.lastname: Futrakul
authors.forename: Tasanee
authors.initials: T
authors.lastname: Panichakul
authors.forename: Punnee
authors.initials: P
authors.lastname: Butthep
authors.forename: Prasit
authors.initials: P
authors.lastname: Futrakul
authors.forename: Pim
authors.initials: P
authors.lastname: Jetanalin
authors.forename: Suthiluk
authors.initials: S
authors.lastname: Patumraj
authors.forename: Prasong
authors.initials: P
authors.lastname: Siriviriyakul
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016923:Cell Death; D003520:Cyclophosphamide / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood / Q000187:drug effects / Q000276:immunology; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy*; D006801:Humans; D009395:Nephritis, Interstitial; D009401:Nephrosis / Q000188:drug therapy; D008517:Phytotherapy / Q000379:methods*; D010946:Plants, Medicinal; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000188:drug therapy*; D020940:Reishi; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D014665:Vasodilator Agents; D003520:Cyclophosphamide; D011239:Prednisolone